Gregory D. Jenkins

Gregory D. Jenkins

Auto-generated profile, based on publicly available information

Gregory D. Jenkins

Department of Quantitative Health Sciences, Mayo Clinic, Rochester, USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 April 2024 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
CNCaroline Nievergelt
Caroline Nievergelt
AMAdam X. Maihofer
Adam X. Maihofer
EAElizabeth G. Atkinson
Elizabeth G. Atkinson
CCChia-Yen Chen
Chia-Yen Chen
KCKarmel W. Choi
Karmel W. Choi
KKKarestan C. Koenen
Karestan C. Koenen

25 April 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
CPCyril Pottier
Cyril Pottier
FKFahri Küçükali
Fahri Küçükali
MBMatt Baker
Matt Baker
ABAnthony Batzler
Anthony Batzler
GJGregory D. Jenkins
Gregory D. Jenkins
RRRosa Rademakers
Rosa Rademakers
Frontotemporal lobar degeneration with neuronal inclusions of the TAR DNA-binding protein 43 (FTLD-TDP) is a fatal neurodegenerative disorder with only a limited number of risk loci identified. We report our comprehensive genome-wide association study as part of the International FTLD-TDP Whole-Genome Sequencing Consortium, including 985 patients and 3,153 controls compiled from 26 institutions/brain banks in North America, Europe and Australia, and meta-analysis with the Dementia-seq cohort. We confirm UNC13A as the strongest overall FTLD-TDP risk factor and identify TNIP1 as a novel FTLD-TDP risk factor. In subgroup analyzes, we further identify genome-wide significant loci specific to each of the three main FTLD-TDP pathological subtypes (A, B and C), as well as enrichment of risk loci in distinct tissues, brain regions, and neuronal subtypes, suggesting distinct disease aetiologies in each of the subtypes. Rare variant analysis confirmed TBK1 and identified C3AR1, SMG8, VIPR1, RBPJL, L3MBTL1 and ANO9, as novel subtype-specific FTLD-TDP risk genes, further highlighting the role of innate and adaptive immunity and notch signaling pathway in FTLD-TDP, with potential diagnostic and novel therapeutic implications.

1 January 2022 in Mayo Clinic Proceedings
Verified
Journal Article
Open access
LRLila J. Jean Finney Rutten
Lila J. Jean Finney Rutten
PPPhilip D. Parks
Philip D. Parks
EWEmily Weiser
Emily Weiser
CFChun Fan
Chun Fan
DJDebra J. Jacobson
Debra J. Jacobson
PLPaul J. Limburg
Paul J. Limburg
To assess health care provider (HCP) preferences related to colorectal cancer (CRC) screening overall, and by HCP and patient characteristics. We developed a survey based on the Theoretical Domains Framework to assess factors associated with CRC screening preferences in clinical practice. The survey was administered online November 6 through December 6, 2019, to a validated panel of HCPs drawn from US national databases and professional organizations. The final analysis sample included 779 primary care clinicians (PCCs) and 159 gastroenterologists (GIs). HCPs chose colonoscopy as their preferred screening method for average-risk patients (96.9% (154/159) for GIs, 75.7% (590/779) for PCCs). Among PCCs, 12.2% (95/779) preferred multi-target stool DNA (mt-sDNA), followed by fecal immunochemical test (FIT), (7.3%; 57/779) and guaiac-based fecal occult blood test (gFOBT) (4.8%; 37/779). Preference among PCCs and GIs generally shifted toward noninvasive screening options for patients who were unable to undergo invasive procedures; concerned about taking time from work; unconvinced about need for screening; and refusing other screening recommendations. Among PCCs, preference for mt-sDNA over FIT and gFOBT was less frequent in larger compared with smaller clinical practices. Additionally, preference for mt-sDNA over FIT was more likely among PCCs with more years of clinical experience, higher patient volumes (> 25/day), and practice locations in suburban and rural settings (compared to urban). Both PCCs and GIs preferred colonoscopy for CRC screening of average-risk patients, although PCCs did so less frequently and with approximately a quarter preferring stool-based tests (particularly mt-sDNA). PCCs' preference varied by provider and patient characteristics. Our findings underscore the importance of informed choice and shared decision-making about CRC screening options.

1 January 2013 in Frontiers in Genetics
Verified
Journal Article
Open access
PDF file
JJJing Jiang
Jing Jiang
BFBrooke Fridley
Brooke Fridley
QFQiping Feng
Qiping Feng
RARyan P. Abo
Ryan P. Abo
Abra BrisbinAbra Brisbin
Abra Brisbin
LWLiewei Wang
Liewei Wang
The mammalian target of rapamycin (mTOR) inhibitors, a set of promising potential anti-cancer agents, has shown response variability among individuals. This study aimed to identify novel biomarkers and mechanisms that might influence the response to Rapamycin and Everolimus. Genome-wide association (GWA) analyses involving single nucleotide polymorphisms (SNPs), mRNA, and microRNAs microarray data were assessed for association with area under the cytotoxicity dose response curve (AUC) of two mTOR inhibitors in 272 human lymphoblastoid cell lines (LCLs). Integrated analysis among SNPs, expression data, microRNA data and AUC values were also performed to help select candidate genes for further functional characterization. Functional validation of candidate genes using siRNA screening in multiple cell lines followed by MTS assays for the two mTOR inhibitors were performed. We found that 16 expression probe sets (genes) that overlapped between the two drugs were associated with AUC values of two mTOR inhibitors. One hundred and twenty seven and one hundred SNPs had P < 10−4, while 8 and 10 SNPs had P < 10−5 with Rapamycin and Everolimus AUC, respectively. Functional studies indicated that 13 genes significantly altered cell sensitivity to either one or both drugs in at least one cell line. Additionally, one microRNA, miR-10a, was significantly associated with AUC values for both drugs and was shown to repress expression of genes that were associated with AUC and desensitize cells to both drugs. In summary, this study identified genes and a microRNA that might contribute to response to mTOR inhibitors.

15 May 2021 in Journal of Immigrant and Minority Health
Verified
Journal Article
Closed access
PDF file
JHJames C. Hill
James C. Hill
JNJane W. Njeru
Jane W. Njeru
MWMark L. Wieland
Mark L. Wieland
LRLila J. Jean Finney Rutten
Lila J. Jean Finney Rutten
DJDebra J. Jacobson
Debra J. Jacobson
CFChun Fan
Chun Fan

13 February 2024 in Translational Psychiatry
Verified
Journal Article
Open access
PDF file
NNNicolas A. Nuñez
Nicolas A. Nuñez
BCBrandon J. Coombes
Brandon J. Coombes
LBLindsay Melhuish Beaupre
Lindsay Melhuish Beaupre
AOAysegul Ozerdem
Aysegul Ozerdem
MRManuel Gardea Resendez
Manuel Gardea Resendez
MFMark A. Frye
Mark A. Frye
There is increasing interest in individualizing treatment selection for more than 25 regulatory approved treatments for major depressive disorder (MDD). Despite an inconclusive efficacy evidence base, antidepressants (ADs) are prescribed for the depressive phase of bipolar disorder (BD) with oftentimes, an inadequate treatment response and or clinical concern for mood destabilization. This study explored the relationship between antidepressant response in MDD and antidepressant-associated treatment emergent mania (TEM) in BD. We conducted a genome-wide association study (GWAS) and polygenic score analysis of TEM and tested its association in a subset of BD-type I patients treated with SSRIs or SNRIs. Our results did not identify any genome-wide significant variants although, we found that a higher polygenic score (PGS) for antidepressant response in MDD was associated with higher odds of TEM in BD. Future studies with larger transdiagnostic depressed cohorts treated with antidepressants are encouraged to identify a neurobiological mechanism associated with a spectrum of depression improvement from response to emergent mania.